- Steri-Med Pharma production capacity doubled compared to 2023
levels
- Phase 2 Production scale-up expected to increase capacity
five-fold by early 2026.
BOUCHERVILLE, QC, Nov. 6, 2024
/CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) , (TSXV: LSL.DB) ("LSL
Pharma" or the "Corporation"), an integrated
Canadian-based pharmaceutical company, announces having secured
$1.4 million on new orders from
international clients, as well as having completed the initial
phase of production scale-up at its Steri-Med Pharma ("Steri-Med")
plan. The initial phase of production scale up has
contributed to more than double the plant capacity compared to 2023
levels, and enabled Steri-Med to win new international contracts
for its existing products.
"We are excited with the progress made to date at our Steri-Med
facility. Historically, production capacity has been a limiting
factor of growth for Steri-Med's revenues. Following
investments made thus far in 2024, we have more units available for
non-Canadian sale", commented Francois
Roberge, President and CEO of LSL Pharma. "Following the
sale of more than 500,000 units of our Erythomycin 1 gram product
to the US over the last year, international demand for Steri-Med's
sterile ointment products is growing. Recently, we have been
successful in opening new sales channels for Steri-Med's products
which contributed to LSL Pharma securing $1.4 million of new orders over the recent
months", added Francois Roberge.
The second phase of production scale-up will include the
installation of a new fully automated sterile ointment production
line (the "Second Line"). The Second Line is expected
to be delivered during the first quarter of 2025 and to be
operational early 2026, following installation and
validation.
"Once operational, the Second Line is expected to increase
Steri-Med's production capacity five-fold compared to our current
1.2 million units production capacity, as well as free-up capacity
to support the development of Steri-Med's first-to-market generic
product pipeline", said Francois
Roberge, President and CEO of LSL Pharma.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements as
defined under applicable Canadian securities legislation.
Forward-looking statements can generally be identified by the use
of forward-looking terminology such as "may", "will", "expect",
"intend", "estimate", "continue" or similar expressions.
Forward-looking statements are based on a number of assumptions and
are subject to various known and unknown risks and uncertainties,
many of which are beyond the Corporation's ability to control or
predict, that could cause actual results or performance to differ
materially from those expressed or implied in such forward-looking
statements. These risks and uncertainties include, but are not
limited to, those identified in the Corporation's filings with
Canadian securities regulatory authorities, such as legislative or
regulatory developments, increased competition, technological
change and general economic conditions. All forward-looking
statements made herein should be read in conjunction with such
documents.
Readers are cautioned not to place undue reliance on
forward-looking statements. No assurance can be given that any of
the events referred to in the forward-looking statements will
transpire, and if any of them do, the actual results, performance
or achievements of the Corporation may differ materially from those
expressed or implied by the forward-looking statements. All
forward-looking statements contained in this press release speak
only as of the date of this press release. The Corporation does not
undertake to update these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) have reviewed or accept responsibility for the
adequacy or accuracy of this release.
ABOUT LSL PHARMA GROUP INC.
LSL Pharma Group Inc. is an integrated Canadian-based
pharmaceutical company specializing in the development,
manufacturing, and commercialization of high-quality sterile
ophthalmic pharmaceuticals, as well as natural health products in
solid and liquid dosage forms. For further information, please
visit our website at www.groupelslpharma.com
SOURCE Groupe LSL PHARMA INC.
